2026.08_Obtaining US patent: Biodegradable Double-J Stentand Method Of Manufacturing The Same, Patent Application No.: 18/444,629.

Horien Biotech (7814) was transferred from the Emerging Stock Market to the OTC Market today (16th). With its overseas expansion and new product development continuing, analysts are optimistic about the company's sustained growth momentum.  Horien Biotech stated that its June revenue increased by 209.29% year-on-year, benefiting from increased demand in Taiwan, the United States, and overseas markets. Regarding its overseas expansion, the company obtained three Class 4 medical device marketing authorizations in Thailand in July, and Class III medical device licenses in the Philippines and Vietnam are expected to be obtained soon, strengthening its presence in the Southeast Asian market. Furthermore, its bio-ink products are expected to be exported to the European market by the end of the year.  In terms of R&D, Horien Biotech's independently developed biodegradable ureteral stent has obtained a Taiwanese invention patent and plans to apply for patents in the United States, Europe, and China. Currently, sample development has been completed and the product has entered the animal testing phase. The company pointed out that the product is expected to improve the problem of traditional ureteral stents requiring a second surgery for removal. In addition, collagen regeneration patches developed using decellularization technology have entered the trial production stage, targeting the surgical and orthopedic tissue repair market.  Regarding supply chain development, its subsidiary, Shengli Biotechnology, has signed memorandums of understanding and cooperation agreements with Taiwan Sugar Corporation and Taiwan Livestock Corporation to establish a supply chain for animal-derived raw materials for medical devices that complies with ISO 13485 and ISO 22442 standards, ensuring the supply of high-end collagen medical device raw materials.  Chairman Tsai Kuo-Tien stated that listing on the OTC market is a significant milestone for the company. Moving forward, the company will continue to deepen its existing markets in dentistry and surgery, and promote the development of high-end medical device products and overseas markets. With the acquisition of international certifications and the progress of new product development, the company expects to drive medium- to long-term operational growth. Report Link: Horien Biotech Lists on the OTC Market Today; Certification Obtained in Thailand, Bio-inks Expand into Europe, Aiming for Overseas Growth Mnews

Horien Biotech (7814), a leading domestic manufacturer of high-end collagen medical devices, listed on the OTC market on the 16th at NT$28.45 per share. The stock price reached NT$32.15 in early trading, a 13.01% increase, initiating a honeymoon period. Horien Biotech Chairman Tsai Kuo-Tien stated that the listing is a significant milestone in the company's development history. In the future, the company will continue to deepen its global market penetration by leveraging top-grade medical-grade raw materials and groundbreaking high-end medical devices, building upon its existing dental and surgical channels.  Horien Biotech, with its strong R&D capabilities and deep technological barriers, has recently delivered outstanding results in revenue performance, international certifications, global market expansion, and the establishment of a top-tier biomedical raw material supply chain. Driven by continued strong demand in the US, Taiwan, and overseas markets, Horien Biotech achieved a remarkable 209.29% revenue increase in June. This success is attributed not only to strong fundamentals but also to breakthrough progress in its overseas expansion.  On July 7th, Horien Biotech successfully obtained three high-risk (highest level, Class 4) medical device market access licenses in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, the Philippines and Vietnam are also expected to obtain Class III medical device licenses soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. Moreover, the company's highly anticipated bio-ink innovative product is planned for official export to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see a surge in global revenue contributions.  In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. The company's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon obtain invention patents in the United States, Europe, and China. Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing. Report Link: Horien Biotech's stock price surged on its first day of trading, with intraday gains exceeding 10% Economic Daily News / Yan Ya-Fang

High-end collagen medical device manufacturer Horien Biotech (7814) listed on the OTC market today (16th) at NT$28.45, with its share price surging as much as 13% at the opening. Benefiting from continued strong demand in the US, Taiwan, and overseas markets, Haichang's revenue increased by 55% year-on-year in the first half of this year. With the continued expansion of regenerative medicine applications and the gradual advancement of several new products, revenue growth momentum is expected to continue in the second half of the year, with the company aiming for profitability for the full year. Horien Biotech has established its R&D advantages through "polymorphic collagen processing technology" and "decellularization technology," enabling it to precisely adjust material properties according to different clinical needs, balancing structural strength, ease of operation, and biocompatibility, while retaining key factors that promote tissue repair. This technology platform not only creates a clear competitive barrier but also helps the company continue to upgrade towards the high-value medical device market, improve the overall product portfolio's gross profit structure, and strengthen its differentiated competitive advantage over its peers.  In addition to the steady growth of its existing products, Horien Biotech is actively developing high-end medical devices, targeting the global market with large-scale potential. Horien Biotech's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to receive invention patents in the US, Europe, and China soon. This product not only solves the clinical pain point of traditional stents requiring secondary surgery for removal but also targets a pristine blue ocean market worth billions of US dollars with no competition. The market widely regards it as a crucial growth engine for Horien Biotech's future, potentially propelling the company into a new phase of rapid growth.  Meanwhile, the collagen regeneration patch developed using its core "advanced decellularization technology," primarily targeting surgical and orthopedic tissue repair, has recently entered the trial production stage, providing a strong profit foundation for its medium- to long-term product line.  In overseas markets, Horien Biotech recently obtained three high-risk (highest level, Class 4) medical device marketing authorizations in Thailand, successfully entering the ASEAN high-end medical device market. Furthermore, it is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its important strategic layout in the Southeast Asian market is nearly complete. Furthermore, the company's highly anticipated bio-ink innovative product is also planned for official export to the European market by the end of this year, extending its international footprint from Asia to Europe and the United States, and its global revenue contribution is expected to see a surge.  With the continued expansion of regenerative medicine applications and the gradual advancement of several new products, collagen-based sheet products are expected to receive certification as early as the fourth quarter and begin contributing to revenue. Analysts are optimistic about continued revenue growth in the second half of the year, maintaining a strong performance for the full year, and striving for profitability. Report Link: Horien Biotech's stock price surged as much as 13% on its first day of trading on the over-the-counter market, with new products and export sales driving continued strong momentum for the second half of the year Investment Weekly / He Mei-Ru

Taiwanese collagen medical device manufacturer Horien Biochemical Technology (7814) officially listed on the OTC market today (July 16). Horien Biochemical Technology has attracted significant attention from the capital market due to its recent outstanding performance in revenue, international certifications, global market expansion, and the establishment of a top-tier biomedical raw material supply chain. The underwriting price was NT$28.47, and the stock price opened at NT$32, a gain of over 12%.  On July 7, Horien Biochemical Technology successfully obtained three high-risk (highest level, Class 4) medical device market licenses in Thailand, successfully entering the high-end medical device market in ASEAN. Furthermore, it is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. In addition, Haichang's highly anticipated bio-ink innovative product is planned to be officially exported to the European market by the end of this year, extending its international footprint from Asia to Europe and America.  In the research and development of advanced innovative medical devices, Horien Biotech's independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and is expected to soon secure invention patents in the United States, Europe, and China. Currently, this innovative product has successfully completed sample development and has been officially delivered for animal testing. As no other company in the industry has yet obtained relevant medical device certifications, Horien Biotech is at the forefront globally.  Horien Biotech Chairman Tsai Kuo-Tien stated that the successful listing on the OTC market is a significant milestone in Horien Biotech's development history. In the future, the company will continue to deepen its global market penetration by leveraging top-grade medical-grade raw materials and groundbreaking advanced medical device drugs, building upon its existing dental and surgical channels. With the acquisition of international certifications and the harvesting phase of its innovative product lines, Horien Biotech will create maximum value for all shareholders and the Taiwanese biotechnology industry through steady and rapid growth. Report link: "Liberty Times" Focus Stock: Horien Biochemical Technology: Shares Soar on First Day of Listing; Southeast Asian High-End Medical Devices Strategy Taking Shape Liberty Times / Chen Yung-Chi

Horien Biotech officially listed on the OTC market today at an underwriting price of NT$28.47. As of now, the stock has reached a high of NT$32.15, a 12.9% increase. Recently, it successfully obtained three high-risk, highest-level Class 4 medical device market licenses in Thailand, opening the door to high-end medical devices in Southeast Asia.  Horien Biotech is expected to obtain Class III medical device licenses in the Philippines and Vietnam soon, signifying that its important strategic layout in the Southeast Asian market is nearing completion. Its highly anticipated bio-ink innovative product is planned to be officially exported to the European market by the end of this year, extending its international footprint from Asia to Europe and America, and is expected to see a surge in global revenue contributions.  In the research and development of high-end innovative medical devices, Horien Biotech has achieved a disruptive world-class breakthrough. Its independently developed "biodegradable ureteral stent" has successfully obtained a Taiwanese invention patent and will soon obtain invention patents in the United States, Europe, and China, targeting a multi-billion dollars blue ocean market.  The innovative product has successfully completed sample development and has been officially delivered for animal testing. Since no other company in the industry has yet obtained the relevant medical device certification, Horien Biotechnology is at the forefront globally. This will not only solve the clinical pain point of traditional stents requiring secondary surgery for removal, but also allow them to access a vast, untapped market worth billions of dollars.  To meet the explosive global demand and ensure a secure supply of high-end medical device raw materials, Horien Biotechnology's subsidiary, Shengli Biotechnology, has officially signed Memoranda of Understanding (MOUs) with Taiwan Sugar Corporation and Taiwan Livestock Corporation, adhering to ISO 13485 (Medical Device Quality Management System) and ISO 22442 (Risk Management of Medical Devices Using Animal Tissue), establishing a high-standard international supply chain for medical-grade animal-derived raw materials.  Horien Biotech Chairman Tsai Kuo-Tien stated that Horien Biotech will continue to deepen its global market penetration based on its existing dental and surgical channels, leveraging top-tier medical-grade raw materials and groundbreaking high-end medical devices and drugs. With international certifications secured and innovative product lines entering their harvest period, Horien Biotech will achieve steady and rapid growth, creating maximum value for all shareholders and the Taiwanese biotech industry. Report Link: Horien Biotech's stock price surged on its first day of trading on the OTC market! It has gained access to ASEAN's high-end medical device market TechNews / Yao Hui-Ru